Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record.

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

Passamonti, Francesco, Elena, Chiara, Schnittger, Susanne, Skoda, Radek C., Green, Anthony R., Girodon, François, Kiladjian, Jean-Jacques, McMullin, Mary Frances, Ruggeri, Marco, Besses, Carles, Vannucchi, Alessandro M., Lippert, Eric, Gisslinger, Heinz, Rumi, Elisa, Lehmann, Thomas, Ortmann, Christina A., Pietra, Daniela, Pascutto, Cristiana, Haferlach, Torsten, Cazzola, Mario · 2011 · Blood

Abstract

Although approximately 95% of patients with polycythemia vera (PV) harbor the V617F mutation in JAK2 exon 14, several mutations in exon 12 have been described in the remaining patients. We conducted a European collaborative study to define the molecular and clinical features of patients harboring these mutations. Overall, 106 PVs were recruited and 17 different mutations identified. Irrespective of the mutation, two-thirds of patients had isolated erythrocytosis, whereas the remaining subjects had erythrocytosis plus leukocytosis and/or thrombocytosis. Compared with JAK2 (V617F)-positive PV patients, those with exon 12 mutations had significantly higher hemoglobin level and lower platelet and leukocyte counts at diagnosis but similar incidences of thrombosis, myelofibrosis, leukemia, and death. In a multivariable analysis, age more than 60 years and prior thrombosis predicted thrombosis. These findings suggest that, despite the phenotypical difference, the outcome of JAK2 exon 12 mutations-positive PV is similar to that of JAK2 (V617F)-positive PV.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-11-316810

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 236

Metadata

Authors
Passamonti, F., Elena, C., Schnittger, S., Skoda, R. C., Green, A. R., Girodon, F., Kiladjian, J.-J., McMullin, M. F., Ruggeri, M., Besses, C., Vannucchi, A. M., Lippert, E., Gisslinger, H., Rumi, E., Lehmann, T., Ortmann, C. A., Pietra, D., Pascutto, C., Haferlach, T., & Cazzola, M.
Venue
Blood
Published
2011-03-10
Volume
117
Issue
10
Pages
2813-2816
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2045477530
Cited by
236
References
0
FWCI
8.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. https://app.cochat.ai/papers/10.1182/blood-2010-11-316810
The paper
Passamonti, F., Elena, C., Schnittger, S., Skoda, R. C., Green, A. R., Girodon, F., Kiladjian, J.-J., McMullin, M. F., Ruggeri, M., Besses, C., Vannucchi, A. M., Lippert, E., Gisslinger, H., Rumi, E., Lehmann, T., Ortmann, C. A., Pietra, D., Pascutto, C., Haferlach, T., & Cazzola, M. (2011). Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. https://doi.org/10.1182/blood-2010-11-316810

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.